Arbutus Biopharma Corporation
Arbutus Biopharma Corporation (ABUS) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
abus · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Arbutus Biopharma Corporation (ABUS) measures how much investors pay for each dollar of the company's trailing earnings. ABUS's current PE ratio of 5.11x is calculated by dividing its stock price of $4.24 by its TTM earnings per share of $0.83. +182.1% elevated vs 5Y avg 1.8x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Arbutus Biopharma CorporationYou ABUS | $838M | 5.11x | — | $0.83 |
 Bicara Therapeutics Inc. Common Stock BCAX | $1.1B | N/A | — | -$2.52 |
 EyePoint Pharmaceuticals, Inc. EYPT | $960M | N/A | — | -$3.17 |
 GH Research PLC GHRS | $1.4B | N/A | — | -$0.79 |
 Kura Oncology, Inc. KURA | $760M | N/A | — | -$3.18 |
 Nanobiotix S.A. NBTX | $1.8B | N/A | — | -$0.50 |
 ProKidney Corp. PROK | $575M | N/A | — | -$0.52 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-0.17 | — | |
2024-12-31 FY2024 | — | $-0.38 | — | |
2023-12-31 FY2023 | — | $-0.44 | — | |
2022-12-31 FY2022 | — | $-0.46 | — | |
2021-12-31 FY2021 | — | $-0.72 | — | |
2020-12-31 FY2020 | — | $-0.84 | — | |
2019-12-31 FY2019 | — | $-2.69 | — | |
2018-12-31 FY2018 | — | $-1.03 | — | |
2017-12-31 FY2017 | — | $-1.54 | — | |
2016-12-31 FY2016 | — | $-7.24 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Arbutus Biopharma Corporation (ABUS) measures how much investors pay for each dollar of the company's trailing earnings. ABUS's current PE ratio of 5.11x is calculated by dividing its stock price of $4.24 by its TTM earnings per share of $0.83.
Frequently asked questions
ABUS pe ratio · 6 questionsABUS's current PE ratio is 5.11x as of 2026-06-08, based on a stock price of $4.24 and TTM EPS of $0.83. Data sourced from Financial Modeling Prep via ABUS's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Arbutus Biopharma Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08